We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Atea Pharmaceuticals, Inc. (AVIR - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Atea Pharmaceuticals, Inc. is a member of our Medical group, which includes 888 different companies and currently sits at #10 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atea Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AVIR's full-year earnings has moved 7.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AVIR has moved about 21% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -5% on a year-to-date basis. This means that Atea Pharmaceuticals, Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Design Therapeutics, Inc. (DSGN - Free Report) . The stock is up 11.5% year-to-date.
For Design Therapeutics, Inc., the consensus EPS estimate for the current year has increased 6.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Atea Pharmaceuticals, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 431 individual companies and currently sits at #154 in the Zacks Industry Rank. On average, stocks in this group have lost 3.2% this year, meaning that AVIR is performing better in terms of year-to-date returns. Design Therapeutics, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Atea Pharmaceuticals, Inc. and Design Therapeutics, Inc. as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Atea Pharmaceuticals, Inc. (AVIR - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Atea Pharmaceuticals, Inc. is a member of our Medical group, which includes 888 different companies and currently sits at #10 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atea Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AVIR's full-year earnings has moved 7.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AVIR has moved about 21% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -5% on a year-to-date basis. This means that Atea Pharmaceuticals, Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Design Therapeutics, Inc. (DSGN - Free Report) . The stock is up 11.5% year-to-date.
For Design Therapeutics, Inc., the consensus EPS estimate for the current year has increased 6.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Atea Pharmaceuticals, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 431 individual companies and currently sits at #154 in the Zacks Industry Rank. On average, stocks in this group have lost 3.2% this year, meaning that AVIR is performing better in terms of year-to-date returns. Design Therapeutics, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Atea Pharmaceuticals, Inc. and Design Therapeutics, Inc. as they attempt to continue their solid performance.